These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29649744)

  • 1. Synthesis of 7β-hydroxy-8-ketone opioid derivatives with antagonist activity at mu- and delta-opioid receptors.
    Ahonen TJ; Rinne M; Grutschreiber P; Mätlik K; Airavaara M; Schaarschmidt D; Lang H; Reiss D; Xhaard H; Gaveriaux-Ruff C; Yli-Kauhaluoma J; Moreira VM
    Eur J Med Chem; 2018 May; 151():495-507. PubMed ID: 29649744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
    Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
    ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.
    Ishikawa K; Mochizuki Y; Hirayama S; Nemoto T; Nagai K; Itoh K; Fujii H
    Bioorg Med Chem; 2016 May; 24(10):2199-205. PubMed ID: 27079125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of N-substituent structural variations in opioid receptor profile of LP1.
    Pasquinucci L; Turnaturi R; Aricò G; Parenti C; Pallaki P; Georgoussi Z; Ronsisvalle S
    Bioorg Med Chem; 2016 Jun; 24(12):2832-42. PubMed ID: 27234885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and localization of delta-, kappa-, and mu-opioid receptors in human spermatozoa and implications for sperm motility.
    Agirregoitia E; Valdivia A; Carracedo A; Casis L; Gil J; Subiran N; Ochoa C; Irazusta J
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4969-75. PubMed ID: 16984994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
    Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
    J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors.
    Pacheco Dda F; Romero TR; Duarte ID
    Brain Res; 2014 May; 1562():69-75. PubMed ID: 24675031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probes for narcotic receptor mediated phenomena. 47. Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.
    Iyer MR; Rothman RB; Dersch CM; Jacobson AE; Rice KC
    Bioorg Med Chem; 2013 Jun; 21(11):3298-309. PubMed ID: 23618710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects.
    Inagaki M; Kume M; Tamura Y; Hara S; Goto Y; Haga N; Hasegawa T; Nakamura T; Koike K; Oonishi S; Kanemasa T; Kai H
    Bioorg Med Chem Lett; 2019 Jan; 29(1):73-77. PubMed ID: 30446313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.
    Ananthan S
    AAPS J; 2006 Mar; 8(1):E118-25. PubMed ID: 16584118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design synthesis and structure-activity relationship of 5-substituted (tetrahydronaphthalen-2yl)methyl with N-phenyl-N-(piperidin-2-yl)propionamide derivatives as opioid ligands.
    Deekonda S; Rankin D; Davis P; Lai J; Vanderah TW; Porecca F; Hruby VJ
    Bioorg Med Chem; 2016 Jan; 24(2):85-91. PubMed ID: 26712115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.
    Kruegel AC; Gassaway MM; Kapoor A; Váradi A; Majumdar S; Filizola M; Javitch JA; Sames D
    J Am Chem Soc; 2016 Jun; 138(21):6754-64. PubMed ID: 27192616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: a comparative study.
    Bera I; Laskar A; Ghoshal N
    J Mol Model; 2011 May; 17(5):1207-21. PubMed ID: 20661609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-Deoxyclocinnamox: the first high-affinity, nonpeptide mu-opioid antagonist lacking a phenolic hydroxyl group.
    Derrick I; Neilan CL; Andes J; Husbands SM; Woods JH; Traynor JR; Lewis JW
    J Med Chem; 2000 Aug; 43(17):3348-50. PubMed ID: 10966754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
    Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
    Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.